Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Quinine
Drug ID BADD_D01895
Description An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Indications and Usage For the treatment of malaria and leg cramps
Marketing Status approved
ATC Code P01BC01
DrugBank ID DB00468
KEGG ID D08460; D08461
MeSH ID D011803
PubChem ID 3034034
TTD Drug ID D03DDR
NDC Product Code 65162-811
UNII A7V27PHC7A
Synonyms Quinine | Quinimax | Quinine Bisulfate | Bisulfate, Quinine | Quinine Hydrochloride | Hydrochloride, Quinine | Myoquin | Quinamm | Quinbisan | Legatrim | Quinine Lafran | Quinine Sulfate | Sulfate, Quinine | Quinine Sulphate | Sulphate, Quinine | Quinine-Odan | Quinoctal | Surquina | Biquinate | Strema | Quindan | Quinbisul | Quinson | Quinsul
Chemical Information
Molecular Formula C20H24N2O2
CAS Registry Number 72402-53-0
SMILES COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoacusis04.02.01.006--
Retinal toxicity12.03.01.036; 06.09.03.0130.003669%Not Available
Lupus-like syndrome15.06.02.004; 10.04.03.003; 23.03.02.004--Not Available
Epigastric discomfort07.01.02.004--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Electrocardiogram U-wave abnormality13.14.05.028--Not Available
Haemorrhage24.07.01.002--Not Available
Antiphospholipid antibodies13.06.01.007--Not Available
Vasodilation procedure25.03.01.001--Not Available
Extremity necrosis24.04.03.012--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Inner ear disorder04.04.02.002--Not Available
Disease recurrence08.01.03.0500.001101%Not Available
Renal impairment20.01.03.010--Not Available
Chronic kidney disease20.01.03.0170.004403%
Acute kidney injury20.01.03.0160.023117%
Retinal pigment epitheliopathy06.09.03.0240.001101%Not Available
Toxic optic neuropathy17.04.05.009; 12.03.01.033; 06.02.08.0030.001101%Not Available
End stage renal disease20.01.03.0190.002936%Not Available
Fixed eruption23.03.05.008; 10.01.01.037; 08.01.06.025--Not Available
Immune thrombocytopenia01.08.01.013; 10.02.01.083--Not Available
The 7th Page    First    Pre   7    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene